A good semaglutide weight loss clinic does more than hand you a prescription. It checks whether the medication is safe for you, starts at a low dose, adjusts it slowly, and stays with you for the long haul, because obesity is a chronic condition that needs ongoing care. At Macie Medical in Katy, our medically supervised weight loss program pairs GLP-1 medication with lifestyle coaching, led by physicians double board-certified in obesity medicine and internal medicine. This guide walks you through what a program involves, who may qualify, what the evidence says, and how to choose a clinic you can trust.
TL;DR
- Semaglutide is an FDA-approved medication for chronic weight management in adults with obesity, or with overweight plus a weight-related condition. It is meant to be used with a reduced-calorie diet and more physical activity.
- In the main clinical trial, adults lost an average of 14.9% of body weight over 68 weeks, compared with 2.4% on placebo. Results vary from person to person.
- Safe care means a medical history review, a slow dose increase and regular follow-up. Nausea and diarrhea are the most common side effects.
- Stopping abruptly often leads to weight regain, so talk to your clinician before making any change.
- Insurance coverage depends on your plan. Our team can walk you through your options before you commit to anything.
Table of Contents
- What a semaglutide weight loss clinic actually does
- Who may qualify for semaglutide
- What happens at your first evaluation
- How a supervised program works: dosing and follow-up
- What results does the evidence show?
- Side effects and precautions
- Eating well on semaglutide
- Our perspective: why we treat weight as a long-term health partnership
- Does insurance pay for semaglutide?
- Paying out of pocket at Macie Medical
- Semaglutide or tirzepatide?
- What to look for in a semaglutide weight loss clinic
- FAQ
- Sources
What a semaglutide weight loss clinic actually does
Semaglutide belongs to a class of medicines called GLP-1 receptor agonists. It mimics a natural gut hormone that helps regulate appetite and blood sugar. But the injection itself is only one piece of the work.
The American Medical Association’s obesity-care guidance describes intensive lifestyle intervention as the foundation of treatment, with medication as one part of medical management, alongside diagnosis, care for related conditions and planned follow-up. That is the standard we hold ourselves to. A clinic worth your time should offer:
- A real medical evaluation, not a questionnaire and a shipping label.
- A prescriber who knows how to adjust the dose and manage side effects.
- Practical guidance on food, protein, hydration and movement.
- Scheduled check-ins, so problems are caught early and progress is measured.
- A plan for what happens after the first goal is reached.
If you are comparing options, you will see telehealth-only services, med spas and primary care practices all offering semaglutide. The difference that matters most is continuity: whether the person prescribing is someone who can follow your health over time, including blood pressure, blood sugar and any other medications you take.
Who may qualify for semaglutide
FDA-approved semaglutide for chronic weight management (sold as Wegovy) is indicated for adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related condition, such as high blood pressure, type 2 diabetes or high cholesterol. The FDA label frames the medication as an addition to a reduced-calorie diet and increased physical activity, and it says not to combine it with another semaglutide product or another GLP-1 receptor agonist.
BMI is a starting point, not the whole story. At your first visit, a clinician looks at your history, your current medications, your other health conditions and what you have already tried.
Who should not take it
Some people should not use semaglutide, and a careful screening is how we find out:
- Thyroid cancer history. The FDA label lists a personal or family history of medullary thyroid carcinoma (MTC), or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), as a contraindication.
- Pregnancy. GLP-1 medications are not recommended during pregnancy because safety data are limited and pregnancy requires appropriate weight gain. If you are planning a pregnancy, tell your clinician before you start.
- Pancreatitis history. Prior pancreatitis is a reason for caution. The VA’s criteria, for example, exclude pregnancy, severe gastrointestinal dysmotility including gastroparesis, and pancreatitis unless its cause is known and no longer a risk.
One detail often surprises patients: the FDA notes that routine calcitonin monitoring or thyroid ultrasound is of uncertain value for early detection of MTC and may lead to unnecessary procedures. So the screening that matters here is a thorough personal and family history, and we take it seriously.
What happens at your first evaluation
We want your first visit to feel unhurried. Here is how it typically unfolds.
- Conversation. We talk about your weight history, what has and has not worked, your goals and your daily routine. We ask about family history, including thyroid conditions.
- Medical review. We go through your conditions and medications, check vital signs such as blood pressure, and decide which tests make sense. If lab work is needed, our on-site lab services keep it convenient.
- Candidacy decision. Together we decide whether semaglutide fits you, or whether another option, such as a different medication or a lifestyle-first plan, is the better path.
- Plan. If you start, you leave with a dose schedule, a follow-up calendar, and clear guidance on what to eat, how to stay hydrated and when to call us.
Because our physicians are board-certified in both obesity medicine and internal medicine, we can look at weight alongside the rest of your health: blood pressure, blood sugar, cholesterol and chronic conditions. You can read more about our weight loss program in Katy.
How a supervised program works: dosing and follow-up
The pace of a program is deliberate. Clinicians start at the lowest dose and increase slowly, no faster than once a month, with ongoing support for side effects. The pivotal STEP 1 trial followed this pattern: weekly semaglutide began at 0.25 mg and rose every four weeks toward a 2.4 mg maintenance dose, alongside lifestyle intervention, over 68 weeks.
Why the slow climb? It gives your body time to adapt and gives us room to hold at a lower dose, or step back, if side effects are hard to manage. Obesity-medicine specialist Dr. Janese Laster told the AMA that patients should choose a prescriber who can provide consistent follow-up, since treatment involves dose titration, possible dose reduction, monitoring for symptoms and drug interactions, adequate food intake and weight-bearing activity.
Here is what follow-up looks like in practice:
- Regular visits during the dose-increase phase to review side effects, appetite, hydration and progress.
- Checks on blood pressure and other measures that matter to you, not just the scale.
- Adjustments to your plan if the medication is not working as expected. The NIDDK explains that if you do not lose at least 5% of your starting weight after 12 weeks on the full dose, your health care professional will probably advise stopping and may change your treatment plan.
- Telemedicine check-ins when an office visit is not necessary, through our cash pay clinic services.
What results does the evidence show?
The strongest numbers come from STEP 1, a 68-week trial in adults with obesity or overweight plus a weight-related condition. Mean body-weight change was −14.9% with semaglutide versus −2.4% with placebo. The share of participants reaching each milestone looked like this:
| Weight loss reached | Semaglutide | Placebo |
|---|---|---|
| At least 5% | 86.4% | 31.5% |
| At least 10% | 69.1% | 12.0% |
| At least 15% | 50.5% | 4.9% |
These are trial averages under study conditions with lifestyle support, and individual results differ. Some people lose more, some less.
The benefits reach beyond the scale. A 2022 analysis of the STEP 1 and STEP 4 trials found semaglutide improved waist circumference, blood pressure, fasting glucose, insulin and lipids versus placebo. It also found those improvements deteriorated after people switched from semaglutide to placebo, which points to the need for long-term management. If heart health is on your mind, our article on how GLP-1 agonists may affect your heart goes deeper.
Lifestyle support also makes a measurable difference. A 2025 joint advisory from four leading nutrition and obesity organizations reports 16% weight reduction with semaglutide plus intensive lifestyle intervention versus 5.7% with lifestyle intervention alone in the STEP 3 trial. That is why coaching is built into our program and not offered as an afterthought.
Side effects and precautions
Most people who take semaglutide notice some digestive effects. In the STEP 1 trial, nausea and diarrhea were the most common adverse events, usually transient and mild to moderate. Even so, gastrointestinal events led 4.5% of semaglutide participants to stop, compared with 0.8% on placebo. That is why the slow dose increase and a clinician you can call matter so much.
There are rarer but serious risks you should know about:
- Pancreatitis. The label reports cases of acute pancreatitis, including fatal and non-fatal forms in patients treated with GLP-1 receptor agonists, and says the medication should be promptly discontinued if it is suspected. Severe, persistent abdominal pain, with or without vomiting, is a reason to call your clinician or seek urgent care right away.
- Gallbladder disease. The same label notes that gallstones and gallbladder inflammation have been associated with Wegovy, with higher rates in trials even after accounting for weight loss. Pain in the upper right abdomen, fever or yellowing of the skin should be evaluated promptly.
If you are ever unsure whether a symptom is routine or urgent, call us. Our urgent care and walk-in services mean you do not have to wait for a scheduled appointment, and same-day visits are part of how we work.
Eating well on semaglutide
Appetite drops on semaglutide, which makes it easy to under-eat protein and fluids. The 2025 advisory emphasizes minimally processed, nutrient-dense foods and fewer starch- and sugar-rich ultraprocessed foods, and says nutrition care should protect diet quality and body composition rather than simply maximize appetite suppression.
Patient guidance in JAMA Internal Medicine recommends:
- Prioritizing protein and eating smaller, nutrient-dense meals.
- Choosing slowly digested carbohydrates and healthy fats.
- Adjusting food choices if you have nausea or constipation.
- Drinking mainly water. The guidance gives a protein target of 1.0 to 1.5 g/kg/day for people doing moderate activity, and 2 to 3 liters of fluid daily.
Treat those figures as a starting point to discuss with your clinician, since kidney disease, heart failure and other conditions can change fluid and protein needs. Our coaching helps you turn them into real meals, whether you are cooking for a family or eating at your desk. If your schedule is packed, our weight loss tips for busy professionals are a good place to start.
Our perspective: why we treat weight as a long-term health partnership
We see semaglutide as a tool, not a shortcut. The patients who do best are the ones who feel supported, who understand what the medication is doing and who have a home base for their health beyond the weight loss itself.
That is why we offer weight management inside a full primary care practice. When the same physician who prescribes your medication also knows your blood pressure, your family history and your lab results, decisions become safer and plans become more manageable. Our double board certification in obesity medicine and internal medicine means we can treat obesity as the medical condition it is, while still looking after the rest of you.
We also believe a program should fit your life. That means honest conversations about cost, realistic goals, and what you will do when the medication is no longer the main driver. Before we recommend any medication, we want to know you are comfortable with the plan, including how you will eventually step down or maintain your progress.
— User
Does insurance pay for semaglutide?
It depends on your plan, your diagnosis and which product is prescribed. Coverage for weight-loss use differs widely between commercial plans, and many plans exclude it. Because of that, we recommend checking with your insurer and talking with our team before you start, so there are no surprises.
Medicare is changing. CMS describes a Medicare GLP-1 Bridge short-term demonstration starting July 1, 2026 that covers Wegovy for eligible Part D patients who cannot receive a GLP-1 through their Part D plan and who do not have type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease. Because it is a temporary demonstration, ask your clinician or the CMS page for current eligibility rules.
Paying out of pocket at Macie Medical
If you prefer a predictable, self-pay arrangement, our cash pay clinic in Katy publishes its pricing: Package 1 is $500 per year, Package 2 is $700 per year, and additional visits are $150 per visit. You can see exactly how these work, along with our telemedicine cash pay services, on our cash pay clinic page. We do not publish a price for the weight loss program itself, so contact us for details tailored to your situation.
Ready to talk through your options? Book an evaluation with our team, and we will help you decide whether semaglutide, another medication or a lifestyle-first plan is the right place to begin. We welcome patients from Katy, Cypress, Richmond, Fulshear and the greater Houston area.
Semaglutide or tirzepatide?
Semaglutide is not the only option. Tirzepatide is another injectable used for weight management, and the right choice depends on your health history, tolerance and goals. Our physicians walk through that decision with you, and you can read our comparison of tirzepatide and semaglutide before your visit.
What to look for in a semaglutide weight loss clinic
Use these questions to compare any program, including ours:
- Who prescribes, and what are their credentials? Look for board certification in obesity medicine or internal medicine.
- Is there a full medical evaluation? Screening should cover thyroid history, pancreatitis, pregnancy plans and current medications.
- How is the dose managed? Expect a low start and gradual increases.
- How often will you be seen? Consistent follow-up is a sign of safe care.
- Is lifestyle support included? Nutrition, protein, hydration and activity guidance should be part of the plan.
- Is the pricing clear? Ask what is included and what is billed separately.
- What is the plan for stopping or maintaining? A good clinic discusses this at the beginning.
For more on what a medical program can offer locally, see our overview of medical weight loss programs in Houston.
FAQ
Can I just stop taking semaglutide?
Please talk to your clinician first rather than stopping abruptly. Yale Medicine advises discussing a transition with a professional, which may involve lifestyle changes, switching medications or bariatric surgery. Research shows people who stop GLP-1 medications often regain a significant portion of the weight they lost.
How do I lose weight successfully with semaglutide?
Combine the medication with a reduced-calorie diet, regular activity and steady follow-up, as the FDA label directs. Prioritize protein and water, eat smaller nutrient-dense meals and report side effects early. Lifestyle support matters: in STEP 3, adding intensive lifestyle intervention was associated with substantially greater weight loss than lifestyle intervention alone.
At what weight will a doctor prescribe weight loss medication?
There is no single number of pounds. Eligibility is based on BMI: 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. Your clinician also weighs your medical history and safety screening before prescribing.
Does a semaglutide program include more than injections?
It should. A well-run program includes a medical evaluation, gradual dose changes, scheduled follow-up and nutrition and activity coaching. At Macie Medical, we combine obesity medicine with individualized lifestyle coaching so your progress is something you can sustain.
Sources
- AMA: 3 treatment keys for obesity care
- Yale Medicine: GLP-1 medications for weight loss
- FDA Wegovy label (2026)
- FDA semaglutide label, contraindications (2026)
- FDA Wegovy label (2023)
- VA semaglutide criteria for weight management
- NIDDK: Prescription medications to treat overweight and obesity
- AMA: Understanding prescription weight loss medication
- STEP 1 trial: Once-weekly semaglutide in adults with overweight or obesity
- Semaglutide and cardiometabolic risk factors, STEP 1 and STEP 4 analysis
- Nutritional priorities to support GLP-1 therapy
- JAMA Internal Medicine: Patient guidance for GLP-1 medications
- CMS: Medicare GLP-1 Bridge information for prescribers
